Table 3.

Patient and graft survival after conversion per group after 1.5-yr follow-up. Incidence of malignancies per groupa

ParameterMMF/PredMMF/CsAMMF/CsA/Pred
a PTLD, posttransplantation lymphoproliferative disorder.
n patients637673
Graft failure212
Patient death022
Malignancies012
    PTLD001
    skin (non-melanoma)011